Loading...
XSHG603566
Market cap628mUSD
Dec 24, Last price  
13.35CNY
1D
-0.60%
1Q
14.20%
Jan 2017
-44.79%
IPO
8.54%
Name

Pulike Biological Engineering Inc

Chart & Performance

D1W1MN
XSHG:603566 chart
P/E
26.28
P/S
3.66
EPS
0.51
Div Yield, %
0.00%
Shrs. gr., 5y
1.57%
Rev. gr., 5y
15.55%
Revenues
1.25b
+2.01%
266,433,955292,354,213412,624,868417,525,649472,081,960475,689,703478,138,171583,102,019529,895,207608,059,265663,194,736928,511,8131,098,568,1031,228,016,4761,252,693,603
Net income
175m
+3.99%
92,759,04283,990,635115,376,126129,212,279162,862,081140,256,921141,742,152188,002,145114,185,865135,614,826109,246,252227,744,103244,137,406167,820,374174,517,388
CFO
283m
+21.30%
000147,960,866181,213,819151,206,579187,086,131253,026,482140,861,979126,271,903140,103,014261,831,612212,533,722233,129,092282,777,231
Dividend
Jun 14, 20240.4 CNY/sh
Earnings
May 16, 2025

Profile

Pulike Biological Engineering, Inc. engages in the research and development, production, and marketing of veterinary biological products and drugs. It offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. The company is headquartered in Luoyang, China.
URL
http://www.pulike.com.cn/
IPO date
May 18, 2015
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
1,252,694
2.01%
1,228,016
11.78%
1,098,568
18.31%
Cost of revenue
977,473
948,456
797,178
Unusual Expense (Income)
NOPBT
275,221
279,560
301,390
NOPBT Margin
21.97%
22.77%
27.43%
Operating Taxes
20,095
9,900
40,039
Tax Rate
7.30%
3.54%
13.28%
NOPAT
255,126
269,661
261,351
Net income
174,517
3.99%
167,820
-31.26%
244,137
7.20%
Dividends
(62,928)
(157,321)
Dividend yield
0.71%
2.26%
Proceeds from repurchase of equity
(7,644)
(150)
BB yield
0.10%
0.00%
Debt
Debt current
7,026
(15,155)
Long-term debt
2,110
428
Deferred revenue
21,603
8,262
6,968
Other long-term liabilities
1
Net debt
(630,619)
(964,945)
(575,940)
Cash flow
Cash from operating activities
282,777
233,129
212,534
CAPEX
(304,981)
Cash from investing activities
(1,662)
Cash from financing activities
(241,029)
829,072
(157,574)
FCF
(4,212)
(55,844)
(14,074)
Balance
Cash
724,794
972,399
243,832
Long term investments
(92,065)
316,952
Excess cash
570,094
910,999
505,856
Stockholders' equity
1,567,300
1,629,010
1,485,363
Invested Capital
2,176,439
1,874,729
1,270,840
ROIC
12.60%
17.15%
21.91%
ROCE
9.99%
9.95%
16.82%
EV
Common stock shares outstanding
349,035
322,433
314,642
Price
22.65
-17.21%
27.36
23.80%
22.10
6.61%
Market cap
7,905,638
-10.38%
8,821,756
26.87%
6,953,582
6.05%
EV
7,275,019
7,856,811
6,377,642
EBITDA
367,951
353,378
360,853
EV/EBITDA
19.77
22.23
17.67
Interest
1,124
728
226
Interest/NOPBT
0.41%
0.26%
0.08%